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Introduction
Intracerebral hemorrhage (ICH) is a subtype of stroke that results 
from the rupture of a blood vessel within the brain parenchyma, often 
due to hypertension (1). ICH has a high mortality rate; 40%–50% of 
patients die within the first 30 days. Currently, there is no specific 
treatment for ICH (1, 2). The exposure of brain tissue to blood com-
ponents results in activation of microglia, the tissue-resident macro-
phages of the central nervous system, and the recruitment of periph-
eral leukocytes to the perihematomal region (3). This early activation 
of the immune system leads to secondary injury after ICH. Activat-
ed microglia and peripheral leukocytes secrete proinflammatory 
cytokines, ROS, and matrix metalloproteinases, which contribute to 
blood-brain barrier breakdown and neuronal injury (3). Microglia and 
blood-derived macrophages, however, can phagocytose the hemato-
ma, resulting in decreased gene expression of Il1b, Tnf, and matrix 
metalloproteinase 9 (Mmp9) (4). The signals that aid in the transition 
to the resolution of inflammation are currently unknown and repre-
sent an important therapeutic target for ICH treatment.
Microglia are often studied in conjunction with peripheral 
macrophages that have infiltrated the brain parenchyma follow-
ing ICH due to the expression of similar surface markers. It has 
recently been shown, however, that unlike blood-derived macro-
phages, microglia derive from yolk sac erythromyeloid progeni-
tors. Microglia develop independently of the transcription factor 
c-Myb and hematopoietic stem cells (5, 6) but are dependent upon 
the transcription factors IRF8 and PU.1 (7). Microglia also have 
a unique molecular signature that is distinct from that of blood- 
derived macrophages (8, 9). These signatures indicate that microg-
lia and blood-derived macrophages likely play distinct roles in dis-
ease pathogenesis and recovery — hence the need to study these 
populations independently.
Tissue-resident macrophages often have prominent roles in 
organ development and homeostasis (10). Indeed, it has recently 
become appreciated that microglia prune neural synapses, guiding 
the development and maintenance of neural networks in the brain 
(11). As the predominant immune population in the central ner-
vous system, microglia are poised to be the first responding cells 
at the site of injury and infection, as well as to aid in tissue repair 
(12, 13). In an autologous blood murine model of ICH, microglial 
activation occurs as early as 4 hours after ICH and can persist for 
up to 4 weeks (14). Microglial activation results in diverse pheno-
typic profiles that have been historically simplified as classical or 
alternative forms of activation. In models of neuroinflammation, 
classically activated microglia have been associated with proin-
flammatory cytokine production and secretion of inducible nitric 
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hypothesized that the changes to the cytokine milieu of the peri-
hematomal region after ICH reflected changes to the activation 
statuses of microglia in this region. Thus, we investigated the phe-
notypic changes specifically in microglia over time after ICH. We 
sorted microglia from perihematomal regions in order to study 
changes in microglial gene expression (Figure 1B). At 12 hours, 
microglial Il6 gene expression was markedly elevated; howev-
er, this was transient, and expression decreased dramatically by 
24 hours and then remained low through day 14. Microglia also 
had elevated Ccl2 gene expression early in the first week that 
decreased by 14 days (Figure 1C).
In order to obtain a more complete understanding of changes 
in microglial gene expression after ICH, we performed a transcrip-
tional analysis of 780 genes from microglia sorted from mouse 
brains over the course of 28 days. Overall, the largest changes in 
gene expression occurred between days 3 and 7 (Supplemental 
Figure 1A, clusters enlarged in Supplemental Figure 1, B–F; sup-
plemental material available online with this article; doi:10.1172/
JCI88647DS1). Principal components analysis (PCA) identified 
78 genes that accounted for the greatest variability in microglial 
gene expression over the time course. Replicate samples separated 
consistently according to time point, indicating that PCA revealed 
distinct temporal patterns in gene expression by identifying genes 
that contribute to the variance across time (Figure 2A, annotated 
in Supplemental Figure 1G). Hierarchical clustering of these 78 
genes across samples is shown in the heat map and shows clear 
patterns of transcription and groupings of samples by time point 
(Figure 2B). The top cluster identifies a set of genes that has low 
expression in naive microglia but high expression at day 1 after 
ICH. These genes include Ly86, Cxcl10, Tnf, Tlr7, Lcp1, and Itga6, 
indicating an activated, proinflammatory phenotype. Microg-
lia then downregulate these genes by day 3. At day 3, the peak of 
peripheral leukocyte recruitment, microglia express high levels 
of several chemokines and cytokines, including Ccl4, Ccl3, Cd14, 
Cd83, Il1a, and Tnfaip3. Several lower clusters identify genes 
with low expression days 1–3 after ICH, with increased expres-
sion beginning on day 7 and continuing throughout the recovery 
phase. These genes provided evidence of ongoing inflammation, 
such as Il6ra, Fcgr1, and Irf5. However, beginning in this period 
we observed upregulation of Tgfbr1, Tgfbr2, and Tgfb1, as well 
as genes associated with cell adhesion and phagocytosis (Cd164 
and Lamp1) and the inhibition of T cell activation (Lag3). We used 
genes that contributed most to this recovery phase phenotype 
in our PCA to perform GO functional enrichment analysis. We 
found that TGF-β receptor binding and signaling pathways were 
significantly enriched, as well as wound healing functions (Fig-
ure 2C). Displaying these genes as a network, we also found that 
these genes were highly coexpressed and had many physical inter-
actions (Figure 2D). Taken together, our results have identified a 
set of gene modules driven by TGF-β signaling that characterize 
microglia in repair and recovery.
Through the canonical signaling pathway, TGF-β1 signals 
via phosphorylation of SMAD2 and SMAD3 proteins (26). Brain 
sections from WT mice at 14 days showed CD11b+pSMAD2+ cells 
in the perihematomal region (Supplemental Figure 2A). At this 
time point, the majority of the blood-derived monocytes had left 
the perihematomal region, suggesting that the CD11b+pSMAD2+ 
oxide species (15). Alternatively activated microglia secrete antiin-
flammatory cytokines and neurotrophic factors, and are associat-
ed with wound healing and repair (12, 16).
Microglial alternative activation is commonly attributed to 
IL-4/IL-13 signaling through STAT6 (16, 17). In the experimental 
autoimmune encephalomyelitis (EAE) murine models of multiple 
sclerosis, mice with a CNS IL-4 deficiency had exacerbated disease 
and reduced microglial YM1, a marker of alternative activation (18). 
IL-4 deficiency resulted in an increase in proinflammatory gene 
expression, larger infarcts, and worse functional outcomes 20 days 
after ischemic stroke (19). IL-10 induces macrophage alternative 
activation (20) and induces SOCS3 to downregulate inflammation 
in macrophages and microglia (21), and overexpression of IL-10 
improves stroke outcomes (22). TGF-β1 has been recently shown 
to play a pivotal role in microglial development and homeostasis 
both in vitro and in vivo (8) and is also capable of inducing wound 
healing responses in macrophages through SMAD2 and SMAD3 
signaling pathways (20, 23, 24). Given the potential for microglia to 
aid in recovery after brain injury and the recently identified unique 
spectrum of microglial responses (25), we aimed to determine the 
activation profiles of microglia during the acute inflammatory and 
resolution phases after ICH and to determine the mediator(s) of 
the activation of microglia during recovery. Using transcription-
al profiling, we identified a molecular signature that characteriz-
es resolution phase of perihematomal microglia. We additionally 
identified TGF-β1 as the most likely mediator. We then confirmed 
the benefit of TGF-β1 in reducing microglial inflammatory cyto-
kine and chemokine expression both in vitro and in vivo. Finally, 
we found that patients with an increased TGF-β1 response during 
the first few days after ICH had improved long-term outcomes 
even after adjusting for ICH severity. Taken together, our results 
identify TGF-β1 as the likely mediator of a reparative phenotype in 
microglia and critical to recovery after ICH.
Results
The perihematomal region transitions from proinflammatory to anti-
inflammatory within the first 2 weeks after ICH. We first sought to 
determine the cytokines and chemokines present in the perihema-
tomal region over the first 2 weeks after ICH in order to identify 
both the factors that could influence microglial polarization and 
the changes in the brain milieu that could be attributed to microg-
lial activation. According to multiplexed ELISA analysis on brain 
tissue homogenate, concentrations of the proinflammatory cyto-
kine IL-6 were elevated 1 and 3 days after ICH and subsequently 
rapidly decreased (Figure 1A). CCL2 and IL-17 were elevated in the 
perihematomal region at 3 days and then decreased. There were 
no changes in IFN-γ or IL-10. IL-4 was undetectable in the perihe-
matomal region at all time points measured, while IL-13 increased 
from baseline to day 3. In contrast, TGF-β1 and brain-derived 
neurotrophic factor (BDNF), factors associated with resolution of 
inflammation and neurogenesis, increased from day 1 to day 10 
and remained elevated at 14 days. Our data indicate that the proin-
flammatory perihematomal brain environment is characterized by 
IL-6, CCL2, and IL-17 during the first 3 days. This milieu changes 
dramatically toward recovery within the first 2 weeks after ICH.
Microglial phenotypes transition from a proinflammatory phe-
notype to an antiinflammatory phenotype a week after ICH. We 
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Instead, these data show that microglia are both producing and sig-
naling through TGF-β1 during the second week after ICH, suggest-
ing that TGF-β1 may have a role in microglia-mediated recovery.
Mice with dysregulated microglia fail to upregulate Tgfb1 gene 
expression and have worse functional outcomes after ICH. Microg-
lia express the chemokine receptor CX3CR1 under homeostatic 
conditions (27). Its ligand, CX3CL1, is constitutively expressed 
by neurons and can either be membrane bound or secreted as 
a chemokine (28). Binding of microglial CX3CR1 to neuronal 
CX3CL1 maintains microglial quiescence (29, 30), and in animal 
models of LPS-induced neuroinflammation, ALS, and Parkinson’s 
cells were likely microglia. In contrast, we did not find evidence 
that astrocytes were responding to TGF-β1 at this time point 
(Supplemental Figure 2B).
Alternative microglial activation has historically been asso-
ciated with IL-4 and IL-13 signaling (15). We did find evidence of 
increased IL-13 in the brain (Figure 1A). Nonetheless, microglial 
gene expression of Il4Ra, the receptor for both cytokines, was not 
upregulated over time. Furthermore, we found no evidence for 
phosphorylation of STAT6 in microglia (Supplemental Figure 2C). 
Our data suggest that IL-4 and IL-13 do not mediate a traditionally 
defined alternatively activated phenotype in microglia after ICH. 
Figure 1. Microglia downregulate proinflammatory genes by 7 days after ICH. (A) Multiplex assays (IL-6, CCL2, IL-17, IFN-γ, IL-10, IL-4, IL-13) and ELISA 
assays (TGF-β1 and BDNF) were performed on brain tissue homogenates of the perihematomal regions of WT mice at baseline and 1, 3, 7, 10, and 14 days 
after ICH. Individual mice represented as one dot with the line at the median value. n = 4–7 mice/time point. (B) Gating strategy to isolate microglia for cell 
sorting experiments. Samples were gated on live singlets prior to leukocytes being found by forward and side scatter. Samples were then gated on side 
scatter, CD45int to separate microglia from peripheral leukocytes and then on CD45int, CD11b+ to obtain microglia. (C) qRT-PCR for Il6 and Ccl2 was performed 
on cell-sorted microglia from CX3CR1-heterozygous mice at baseline, 12 hours, and 1, 3, 7, and 14 days after ICH. Means graphed with SEM; n = 7–16. Results 
in A and C were analyzed by ANOVA followed by Tukey’s post hoc test; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Figure 2. Temporal transcriptional analysis of microglia after ICH. (A) Scatter plots show each sample projected on the first two principal components 
and are color coded according to time point. Biological replicates cluster closely at each time point. (B) Heatmap of the Z score of genes identified by PCA 
for each sample. Data were clustered hierarchically in GENE-E using one minus Pearson correlation and complete linkage. Data are colored according to 
row minimum and maximum. Time points are color coded as in A, and days 10–28 cluster most closely. Each replicate includes microglia from 3 brains, and 
there are 3 biological replicates per time point. (C) GO biological process enrichment analysis was performed using genes appearing in the resolution phase 
quadrant of the PCA. TGF-β1 pathways account for the majority of the top 15 GO functions. (D) The network diagram shows each gene identified in the 
resolution phase, including TGF-β1, as a node, and connections are indicated by function.
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around the minimal residual hemorrhage with obvious costaining 
of pSMAD2 at 14 days. In contrast, the CX3CR1-null BM chimeras 
had a more widespread region of activated CD11b+ cells and many 
fewer CD11b+pSMAD2+ cells in the perihematomal region (Figure 
3B). These findings indicate that in the absence of CX3CR1 signal-
ing, the microglia do not modulate the phenotype to either pro-
duce or signal through TGF-β1 in the recovery phase of ICH.
We next performed behavioral tests on WT and CX3CR1-null 
BM chimeras to determine whether there is a functional conse-
quence to failing to modulate microglial phenotype. There were no 
behavioral differences between naive WT and CX3CR1-null BM 
chimeras on cylinder and beam walking tests (Supplemental Fig-
ure 3, B and C), indicating no baseline functional effect of lacking 
microglial expression of CX3CR1. After ICH, the two genotypes 
had similar weight loss at 24 hours and displayed equal neurologi-
cal deficits at 24 and 72 hours (Figure 3C and Supplemental Figure 
3D), suggesting microglial CX3CR1 does not impact acute inflam-
mation. Consistent with the reduction in TGF-β1 signaling during 
the recovery phase, the CX3CR1-null BM chimeras exhibited a 
right forelimb preference, showing a left hemiparesis, impaired 
disease, CX3CR1-null mice have worse functional outcomes and 
elevated levels of IL-1β after LPS-mediated neuroinflammation 
(30, 31). We therefore utilized the CX3CR1 regulation of microg-
lial phenotype as a model system for studying the microglial 
responses in recovery after ICH.
Monocytes and several other leukocyte populations also 
express CX3CR1. In order to study CX3CR1 on microglia spe-
cifically, we made bone marrow (BM) chimeras using WT and 
CX3CR1-null mice as hosts and congenically marked WT BM as 
the donor (Supplemental Figure 3A). As microglia are radioresis-
tant and should remain of host origin after irradiation (32), this 
experimental design allows for comparison of WT and CX3CR1-
null microglia after ICH in mice with an otherwise WT immune 
compartment. CX3CR1-null microglia had a significant reduction 
in TGF-β1 gene expression at 14 days compared with WT microglia. 
Differences between the genotypes were not observed in microgli-
al gene expression of alternatively activated markers Bdnf, Socs3, 
Cd206 (Mrc1), or Tgfbr1 (Figure 3A). We examined the perihema-
tomal region by immunofluorescence and found that the WT BM 
chimeras had a very contracted region of amoeboid CD11b+ cells 
Figure 3. Microglial alternative activation is required for functional recovery after ICH. (A) Microglia were cell sorted from WT and CX3CR1-null BM 
chimeras 14 days after ICH and then processed for qRT-PCR. CX3CR1-null microglia have a significant reduction in TGF-β1 gene expression compared with 
WT microglia. Means graphed with SEM; Student’s t test; n = 7–9. (B) Brain sections from WT and CX3CR1-null BM chimeras were stained for CD11b (red) 
and pSMAD2 (green) 14 days after ICH. Nuclei were stained with DAPI. ×40 images, with inset at ×64. Scale bars: 25 μm. Quantification of percent of 
pSMAD2+, amoeboid CD11b+ graphed as mean with SD; Student’s t test; n = 4. (C) BM chimeras were cylinder tested 1, 3, 7, and 14 days after ICH. CX3CR1-
null chimeras maintain a right forelimb preference 14 days after ICH. Means graphed with SEM. Repeated measures ANOVA followed by Tukey’s post hoc 
test; n = 10–12. (D) Beam walking test shows that CX3CR1-null BM chimeras do not walk as well on the beam 14 days after ICH. Percentage of mice able 
versus unable to walk is graphed. Wilcoxon rank sum test; n = 11–13. (E) Forced run test shows that CX3CR1-null BM chimeras do not run as quickly as WT 
BM chimeras 14 days after ICH. Individual dots represent individual mice, with line at the median; Mann-Whitney U test, n = 10–15. *P < 0.05, ***P < 0.001.
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beam walking, and slower top running speeds at 14 days after ICH 
(Figure 3, C–E). Our data suggest that microglial CX3CR1 signal-
ing on microglia is required for phenotype modulation and func-
tional recovery after ICH and support the hypothesis that TGF-β1 
mediates microglial alternative activation.
TGF-β1 modulates microglia-mediated neuroinflammation in 
vitro. In order to directly measure the effects of TGF-β1 on microg-
lia, we next determined whether TGF-β1 modulates microg-
lia-mediated neuroinflammation in vitro. Activated primary 
microglia respond to TGF-β1 in vitro, as indicated by an increase 
in pSMAD2/3 (Figure 4A). Thrombin is a serine protease activated 
during coagulation, present at high levels in ICH, and is frequently 
used as the stimulus to mimic ICH in vitro (33, 34). Consistent with 
our in vivo results, stimulation of microglia with thrombin resulted 
in an upregulation of the genes Il6, Tnf, and Ccl2. These inflam-
matory responses were reduced by TGF-β1 (Figure 4B). Thrombin 
treatment also resulted in a reduction in Tgfb1 and Tgfbr1 gene 
expression; TGF-β1 treatment restored Tgfbr1 gene expression. 
The effects of thrombin and TGF-β1 were then confirmed at the 
protein level. After 8 hours of stimulation, intracellular cytokine 
staining showed that primary microglia activated with thrombin 
and TGF-β1 produced less TNF than those activated with throm-
bin alone (Figure 4C); ELISA of the cell culture supernatant like-
wise revealed decreased levels of IL-6 and TNF after treatment 
with TGF-β1 (Figure 4D).
TGF-β1 treatment reduced microglial inflammation and improves 
functional outcomes 24 hours after ICH. We next examined wheth-
er TGF-β1 induces a microglia phenotype that improves function-
al recovery after ICH. To specifically target the microglia in the 
perihematomal region, mice were initially pretreated with 10 ng 
TGF-β1 or vehicle intracerebrally immediately prior to subject-
ing the mice to ICH. Mice given TGF-β1 treatment had improved 
functional outcomes on cylinder test and the beam walking test at 
24 hours (Supplemental Figure 4).
In order to test whether TGF-β1 can improve functional recov-
ery after ICH in a more translationally relevant time frame, we 
Figure 4. TGF-β1 modulates microglia-mediated neuroinflammation in vitro. (A) Primary microglia respond to TGF-β1 treatment and signal through 
pSMAD2/3 after 15 minutes of stimulation in vitro. Representative histogram shown with fluorescence minus one (FMO) (gray), thrombin treated (red), and 
thrombin + TGF-β1 (blue); n = 3. (B) Thrombin + TGF-β1–treated microglia have a reduction in Il6, Ccl2, and Tnf gene expression and an increase in Tgfbr1 gene 
expression compared with microglia treated with thrombin alone after 8 hours of stimulation. Means graphed with SEM. n = 5 individual experiments with 
3 technical replicates per group, per experiment. unstim, unstimulated. (C) Microglia treated with thrombin + TGF-β1 have reduced TNF production after 8 
hours of stimulation. Means graphed with SEM. Representative histograms show FMO (gray), unstimulated (purple), TGF-β1 alone (blue), thrombin (red), 
and thrombin + TGF-β1 (black). n = 8. (D) TNF and IL-6 ELISA on cell supernatants taken after 24 hours of stimulation. Individual wells are represented by 
dots, with line at the median; n = 5. All statistical analysis performed by ANOVA, followed by Tukey’s post hoc test. *P < 0.05, **P < 0.01, ***P < 0.001.
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treated mice with either TGF-β1 or PBS intracerebroventricular-
ly 4 hours after ICH. Confirming the feasibility of this approach, 
CD11b+pSMAD2+ cells were found in the perihematomal region 
of the TGF-β1–treated mice at 24 hours, a time point prior to the 
induction of the TGF-β1 pathway in untreated mice (Figure 5A). 
Mice treated with a single dose of TGF-β1 4 hours after ICH had 
completely recovered motor function at 24 hours (Figure 5B). This 
recovery persisted for at least 1 week. TGF-β1 treatment also sig-
nificantly reduced ICH-induced microglial Il6 gene expression 
(Figure 5C). We then confirmed this beneficial effect of TGF-β1 
treatment in the collagenase model of ICH, which produces a more 
severe hemorrhage with prolonged functional recovery (35). Mice 
treated with a single dose of TGF-β1 had better functional out-
comes by cylinder test (Figure 5D) and corner test (Figure 5E) at 3 
and 7 days after ICH. We did not observe a difference between the 
treatment groups in microglial numbers at 24 hours, in iron-posi-
tive cells at day 7, or in leukocyte recruitment (Supplemental Fig-
ure 5). Overall, these data suggest that TGF-β1 targets microglia 
and improves behavioral outcomes independent of TNF, CCL2, 
leukocyte infiltration, and hematoma clearance.
TGF-β1 response is associated with improved outcomes at 90 days 
in patients with ICH. In the murine model, TGF-β1 levels were 
high in the naive state in both perihematomal brain tissue and 
in microglia, decreased acutely after ICH, and began to increase 
again around day 7. A similar trend was observed in circulating 
(peripheral) TGF-β1 levels over time in the mouse model (Supple-
mental Figure 6). In addition, administration of TGF-β1 at a time 
point earlier than TGF-β1 was normally induced led to improved 
outcomes in mice. Although there is no way to measure TGF-β1 
levels in patients prior to their experiencing ICH, we hypothesized 
that patients would also have an acute reduction in TGF-β1 after 
ICH that would then recover. Furthermore, we hypothesized that 
earlier TGF-β1 recovery in the acute phase after ICH would be 
associated with better long-term outcomes in patients. We mea-
sured plasma TGF-β1 concentrations in patients at 6 and 72 hours 
after ICH in a prospective cohort study and in a cohort of control 
patients with similar ages and rates of hypertension, the primary 
risk factor for ICH. The clinical characteristics of the patients are 
shown in Supplemental Table 1. As expected, at 6 hours after ICH, 
the levels of TGF-β1 were lower than in the control cohort (ICH 
315.9 pg/ml vs. control 841 pg/ml, P < 0.001) (Figure 6A).
Functional outcomes of patients were measured using the 
modified Rankin scale, the most commonly used scale to quanti-
fy disability after stroke (35, 36). Interestingly, about half of our 
patients had increased TGF-β1 levels from 6 to 72 hours (assumed 
to be early recovery of TGF-β1), while half had decreased TGF-β1 
(prolonged suppression of TGF-β1) (Figure 6A). The two cohorts 
were balanced in age, sex, and stroke severity measures (Table 1). 
Figure 5. TGF-β1 treatment promotes better 
functional outcomes and modulates microg-
lial IL-6 after ICH. (A) TGF-β1 treatment led to 
phosphorylation of SMAD2 in myeloid cells in the 
brain. Brain sections from PBS- or TGF-β1–treat-
ed mice were stained at 24 hours for CD11b (red) 
and pSMAD2 (green). Nuclei were stained with 
DAPI. Arrow indicates cluster of pSMAD2+CD11b+ 
cells. Dotted line depicts edge of hematoma. 
40×, with inset at 64×. Scale bars: 25 μm. n = 
4–5. (B) Cylinder test shows that TGF-β1–treat-
ed mice have better functional outcomes 24 
hours after ICH. Repeated measures ANOVA, 
followed by a Tukey’s post hoc test; n = 11–12. (C) 
TGF-β1–treated microglia have reduced Il6 gene 
expression 24 hours after ICH. Means graphed 
with SEM; Student’s t test; n = 7–9. (D and E) 
TGF-β1–mediated improvements in behavioral 
outcomes were confirmed using the collagenase 
model of ICH. Cylinder test (D) and corner test (E) 
show TGF-β1–treated mice have better functional 
outcomes at 3 and 7 days after ICH. Repeated 
measures ANOVA, followed by Tukey’s post hoc 
test; n = 9–10. *P < 0.05, ***P < 0.001.
Downloaded from http://www.jci.org on June 2, 2017.   https://doi.org/10.1172/JCI88647
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
2 8 7jci.org   Volume 127   Number 1   January 2017
of genes that were upregulated on day 1 were already suppressed 
by day 7. Interestingly, when the entire gene set was clustered by 
time point, day 3 microglia clustered closest to the naive microglia. 
This was unexpected, as day 3 is the peak of peripheral leukocyte 
infiltration after ICH and considered to be the peak of the inflam-
matory response. These findings are reminiscent of findings in 
EAE, where at disease onset microglia upregulated chemokines 
but otherwise exhibited suppressed activation and metabolic phe-
notype compared with naive microglia (41). These similar find-
ings may suggest that this phenomenon is conserved in microglia 
across various diseases.
In our model, microglia obtain a phenotype associated with 
recovery starting at day 7, which remains upregulated through day 
28. The majority of the genes in these clusters were expressed in 
the naive state, decreased on days 1–3, and then recovered begin-
ning at day 7 to reach levels higher than baseline by day 28. Includ-
ed in this set are several genes associated with microglia, includ-
ing P2ry12, Tgfbr1, Cx3cr1, and Mertk, suggesting that these genes 
are differentially regulated in the mouse during inflammation and 
may have roles in the resolution of inflammation. Overall, our 
work helps to identify gene pathways in the tissue-resident popu-
lation of the CNS. By specifically studying microglia, we identified 
that TGF-β1 mediates the pathways involved in microglial recov-
ery after ICH, a finding with potential therapeutic implications.
In recent years, microglial responses have been primarily 
dichotomized into two categories: classical, or proinflammatory, 
activation; and alternative activation, a phenotype associated with 
wound healing, tissue repair, and antiinflammatory properties (15, 
42). Alternative activation has been attributed to IL-4 and IL-13 
signaling on microglia (15). Microglia are often defined as alter-
natively activated through cell surface marker expression; YM1, 
FIZZ1, arginase 1, CD206, CD301, and CD163 are most common-
ly used to distinguish alternatively activated microglia from clas-
sically activated microglia. We did not observe significant changes 
over time in the transcription of conventional markers of alterna-
tive activation in microglia after ICH. Rather, our findings suggest 
that microglia transition to a phenotype that is a type of alternative 
activation that contributes to brain recovery, a phenotype that we 
would not have been able to define using traditional methods and 
markers. Consistent with our findings, TGF-β1 has been shown to 
Using this dichotomy in TGF-β1 response, we explored the func-
tional outcomes of patients at 90 days and found a marked shift 
toward improved outcomes in the patients who increased their 
circulating TGF-β1 levels by 72 hours after ICH (Figure 6B). In 
univariate analysis, an increase in TGF-β1 was associated with 
improved functional outcome, while other clinical variables were 
not associated with TGF-β1 response (Table 1). However, several 
of these variables have strong associations with functional out-
come and had trends toward greater severity among the patients 
who had decreased TGF-β1. Clinically these have been combined 
into the ICH score (37), a prognostic scoring system that includes 
Glasgow coma scale score, age, infratentorial location, intraven-
tricular hemorrhage, and volume of the hemorrhage. Therefore, 
a multivariable model was created adjusting for the impact of 
ICH score on functional outcomes. Patients who had an increase 
in plasma TGF-β1 concentrations from 6 to 72 hours had better 
outcomes by 90 days, independent of known predictors of clini-
cal outcome (n = 22, Table 2). Thus, our data show that TGF-β1 is 
highly associated with functional recovery after ICH in patients.
Discussion
Under basal conditions, tissue-resident macrophages are seeded 
into their respective organs during development to maintain tissue 
homeostasis (13, 38–40). Thus, they are poised for immunosur-
veillance and to act as first responders to potential pathogens (39). 
Because of the robust infiltration of blood-derived macrophages 
during inflammation and the difficulties differentiating the cells 
in tissue, the specific role of tissue-resident macrophages in dis-
ease models of tissue injury is not well defined. Here, we show 
that microglia dramatically transition phenotypes within the first 
2 weeks after ICH and that this transition is critical for functional 
recovery. We also show that TGF-β1 modulates the microglial phe-
notype and promotes functional recovery.
Microglia have dynamic changes in gene expression after 
ICH, expressing proinflammatory genes early after ICH before 
transitioning to a transcriptional program associated with tissue 
repair. Through transcriptional profiling, we identified the genes 
that contribute significantly to the temporal evolution of microglia 
phenotype. In the acute phase (day 1), microglia have a proinflam-
matory phenotype, yet this response was transient, as the majority 
Figure 6. An increase in TGF-β1 plasma levels from 6 to 72 hours after ICH is independently associated with better patient outcomes at 90 days. Plasma 
TGF-β1 concentrations were measured from controls and ICH patients at 6 ± 6 and 72 ± 6 hours after onset of ICH. (A) Each control patient’s TGF-β1 plasma 
level is depicted as a gray dot, with the line indicating the median. Each individual patient’s TGF-β1 plasma level is depicted as a dot, with a line connecting 
each patient’s 6- and 72-hour data. Those who had a decrease in TGF-β1 plasma are depicted in red. (B) Distribution of patient outcomes on the modified 
Rankin scale by TGF-β1 response. n = 22 controls and 22 ICH patients.
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phenotypes after ICH or find evidence that astrocytes 
respond to TGF-β1 at 14 days after ICH, it is possible that 
astrocytes provide the early source of TGF-β1 that initi-
ates the phenotype modulation in microglia.
We used the CD45intCD11b+ classification of microg-
lia in WT mice (51–53), which matched the high CX3CR1 
expression in microglia from our BM chimeras and also 
was recently reported to closely match expression of the 
microglial marker TMEM119 (9). Our in vitro work relied 
on primary microglia, eliminating concerns about phe-
notypic differences observed in immortalized microglial 
cell lines (8). This provides a robust data set that furthers 
our understanding of microglial biology.
Interestingly, we also found that TGF-β1 response in 
patients is an independent predictor of patient outcome 
after ICH, which we believe to be a novel finding. The 
source of the TGF-β1 measured in ICH patients’ plasma 
remains unclear. The murine time course of changes in 
the periphery match changes in the brain, suggesting that they are 
linked, perhaps due to breakdown of the blood brain barrier. It is 
likely that peripheral platelets, leukocytes, astrocytes, and microg-
lia all contribute to the TGF-β1 concentrations measured in ICH 
patients’ plasma. Taken together, our data show that microglia tran-
sition from a proinflammatory phenotype early after ICH into a phe-
notype that promotes wound healing and repair and that this occurs 
independent of IL-4 and IL-13 signaling. Our data indicate that 
TGF-β1 modulates microglia-mediated neuroinflammation after 
ICH and promotes functional recovery in both mice and humans.
Methods
Animals. Male B6.SJL-Ptprca Pep3b/BoyJ (CD45.1), C57/BL6J (WT), 
and B6.129P-Cx3cr1tm1Litt/J (Cx3cr1GFP/GFP and Cx3cr1+/GFP) mice 
were purchased from The Jackson Laboratory and then were bred in 
house. All mice were housed in standard conditions with a 12-hour 
light cycle, 22.2°C, and ad libitum access to food and water.
BM chimeras. To specifically study the role of microglial CX3CR1 
after ICH, we made BM chimeras as previously described (54). Male 
WT and CX3CR1-null mice (congenically marked CD45.2) 6–8 weeks 
of age were irradiated with 12 Gy and reconstituted with BM from a 
WT donor congenically marked CD45.1, herein referred to as WT BM 
chimeras and CX3CR1-null BM chimeras. BM was allowed to engraft 
8–10 weeks prior to ICH surgery. Percent chimerism was measured at 
8 weeks after BM engraftment by flow cytometry. Successful chime-
rism was defined as the presence of at least 90% CD45.1+ leukocytes.
induce a form of alternative activation in macrophages (43, 44). 
Our data show that TGF-β1 drives microglial alternative activation 
in a clinically relevant in vivo model of disease.
The importance of TGF-β1 on microglia development and 
homeostasis and the role of TGF-β1 and TGFBR1 after different 
neurological disease have recently been reported (8, 45–47). Tgfb1 
and Tgfbr1 gene expression are highly upregulated in WT microg-
lia during the second week after ICH. We found that CX3CR1-
null BM chimeras do not functionally recover after ICH and 
CX3CR1-null microglia have a significant reduction in Tgfb1 gene 
expression. Our data suggest that microglial TGF-β1 is important 
in the microglial transition from proinflammatory to reparative 
after ICH. In vitro, TGF-β1 reduced microglial Ccl2, Tnf, and Il6 
gene expression and IL-6 secretion. In vivo, TGF-β1 treatment 
improved functional outcomes and decreased microglial IL-6 
gene expression. It has recently been shown that trans-signaling of 
Il6 through soluble IL-6R and transmembrane gp130 contributes 
to gliosis, blood-brain barrier breakdown, and neurodegeneration 
(48). This raises the possibility that the quelling of microglial IL-6 
is critical in functional recovery after ICH; however, this requires 
further investigation. Interestingly, we were able to show that one 
dose of TGF-β1, when given after ICH in two separate models of 
ICH, improved functional outcomes that persisted, suggesting 
that TGF-β1 has a potentially long-lasting therapeutic effect.
Our work builds on evidence of the importance of TGF-β1 
emerging from other CNS disease models. Silencing of TGF-
BR1 on microglia promoted neuroinflammation and neuronal 
damage in a model of Parkinson’s disease (46). However, early 
astrocyte production of TGF-β1 appears to establish a permissive 
environment for autoimmunity and enhanced inflammation in 
EAE (49). In a rat model of ischemic stroke, TGFBR1 was upreg-
ulated on microglia (47), although no functional role was inves-
tigated. Astrocyte signaling through TGF-β1 has been shown to 
limit neuroinflammation after experimental ischemic stroke. In 
Ast-Tbr2DN mice, which carry dominant negative mutant type II 
TGF-β receptor, inhibition of astrocytic TGF-β1 signaling led to a 
decrease in TGF-β1 levels in brain, enhanced inflammation, and 
impaired long term outcomes. However, effects on microglia phe-
notype were not assessed (50). While we did not assess astrocyte 
Table 1. Univariate analyses of the clinical cohort by TGF-β1 response
Variable TGF-β1 increase TGF-β1 decrease P
Age (yr) 65 [59.2–69.2] 74.65 [59.05–78.5] NS
Male sex 6 (46%) 6 (50%) NS
ICH volume (ml) 9.1 [2.5–22.5] 12.4 [6.1–51.6] NS
Intraventricular hemorrhage 5 (38%) 5 (42%) NS
Infratentorial location 2 (15%) 0 (0% NS
Initial GCS score 15 [14–15] 14 [13–15] NS
ICH score 0 [0–1] 1.5 [1–2] NS
Infection within 72 hours 1 (8%) 3 (25%) NS
mRS at 90 days 2 [1.5–3] 4.5 [3–6] < 0.01
NS: P > 0.05. Data presented as mean ± SD when data were normally distributed; 
median [interquartile range] when data were not normally distributed; and number 
(percentages). GCS, Glasgow coma scale; mRS, modified Rankin scale.
Table 2. TGF-β1 response is independently associated with 
functional outcome at 90 days
Variable OR 95% CI P
TGF-β1 response 0.08 0.01–0.57 0.01
ICH score 2.99 1.33–6.69 0.008
Ordinal logistic regression model of TGF-β1 response and patient 
outcomes adjusted for the ICH score. An increase in TGF-β1 from 6 to 72 
hours was independently associated with better functional outcome.  
n = 22. OR, odds ratio.
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100 U/ml penicillin and 100 mg/ml streptomycin, and 30% L929 
media (glial conditioned media; refs. 62, 63). Cells were allowed to 
rest for 4–5 days prior to use. Primary microglia were treated with 10 
ng TGF and 10 U/ml thrombin for 8 or 24 hours in serum-free X-VIVO 
media (Lonza). Cells were harvested from plates using Accutase 
(Thermo Fisher Scientific) and used for quantitative RT-PCR (qRT-
PCR) or intracellular cytokine staining.
Cell sorting for qRT-PCR and transcriptional analysis. Mice were 
sacrificed 0.5, 1, 3, 7, and 14 days after ICH and perfused with 40 ml 
cold PBS. Perihematomal brains were harvested and mechanically 
and enzymatically digested with DNase, dispase, and collagenase for 
45 minutes at 37°C. Brains were then placed on a 30%/70% Percoll 
gradient to isolate leukocytes and remove myelin. Cells were washed 
and stained with antibodies for cell surface markers (CD45 [30-F11], 
Ly6C [HK1.4, eBiosciences], CD11b [M1/70], Ly6G [1A8, Tonbo Bio-
sciences], CD3e [500A2, BD Biosciences]) for 20 minutes at room 
temperature. Microglia were identified as CD45intCD11b+ cells for WT 
experiments and CD45.2intCD11b+ cells for chimeric experiments, and 
were sorted on a FACSAria. The microglia population was confirmed 
by high CX3CR1 expression. RNA was extracted from sorted microg-
lia and primary microglia using a commercially available kit (RNAque-
ous-Micro, Ambion). cDNA from sorted microglia was synthesized 
with Sensiscript reverse transcriptase (QIAGEN). RNA from primary 
microglia was extracted and cDNA synthesized using SuperScript 
IV (Life Technologies). qRT-PCR was performed using SYBR Green 
(QIAGEN) for the following genes: β-actin, Tnf, Il6, Ccl2, Tgfbr1, Socs3, 
Bdnf, Cd206 (Supplemental Table 2), and Tgfb1. Cell culture samples 
were analyzed by normalizing gene of interest expression to β-actin. 
Sorted microglial samples for qRT-PCR were analyzed using the ΔΔCt 
method (64). In experiments for unbiased transcriptional analysis, 
three 4-mm perihematomal sections of brain were pooled per repli-
cate and brains were processed as above. Microglia (CD45intCD11b+) 
were sorted, and cells were lysed in 4 μl RLT buffer (QIAGEN) and 10 
μl RNA samples directly hybridized with a pool of 780 capture probes; 
gene expression was analyzed by nCounter Digital Analyzer accord-
ing to the manufacturer’s instructions (NanoString Technologies). The 
gene expression was normalized to positive controls and housekeep-
ing genes and calculated as relative counts.
Transcriptional analysis. NanoString data were preprocessed 
according to the manufacturer’s instructions and then further ana-
lyzed using custom MATLAB scripts. Briefly, nCounter data were 
normalized to housekeeping genes, and genes with expression below 
the threshold of detection at all time points were eliminated. Result-
ing nCounter data were imported into MATLAB and Z score normal-
ized. To remove genes that did not significantly change over time, two 
MATLAB functions were used: genevarfilter and geneentropyfilter. 
The former removes genes that have a variance above a specified per-
centile, where variance is calculated for each gene profile. The latter 
removes genes whose profile is low entropy overall. The remaining 
genes were clustered hierarchically to identify 15 clusters of genes 
based on coloring the dendrogram (distance of 6).
To identify genes driving change over time, PCA was performed, 
and results were presented as a biplot. In order to find genes that con-
tribute “the most,” a circle was drawn whose radius was the average of 
the 90th percentile of the magnitude of the principal component coef-
ficients. The goal of using this circle was to allow for consistent iden-
tification of genes. Genes whose projections were on or outside this 
ICH surgery. Mice were anesthetized with 1%–5% isoflurane, and 
all efforts were made to minimize pain and suffering. For experiments 
using the blood injection model of ICH, ICH was induced by injection 
of 20–25 μl whole blood 2.5 mm lateral to bregma, 3 mm deep at a 5° 
angle as previously described (55). For experiments using BM chime-
ras, whole blood from a WT donor was used to create the hemorrhage. 
It has previously been shown that the cellular composition of the ICH 
impacts functional outcome and the inflammatory response in mice 
(56); therefore, WT blood was used to normalize the ICH components 
between genotypes. Chimeras were 13–15 weeks of age when ICH 
was induced. For experiments performed on WT mice, mice were 
8–10 weeks of age when ICH was induced. We used the collagenase 
model of ICH, which results in the degradation of the vascular base-
ment membrane ICH for confirmatory experiments. Briefly, ICH was 
induced by injection of 0.05 U type VII collagenase VII (from Clostrid-
ium histolyticum; Sigma-Aldrich) in 1 μl PBS at the same coordinates as 
the blood injection model.
TGF-β1 treatment. Mice were treated with 10 ng TGF-β1 or vehi-
cle (PBS) in a final volume of 1 μl (45). Mice were randomized by coin 
flip into either TGF-β1 or PBS treatment groups. For behavioral exper-
iments in which mice were pretreated, TGF-β1 or PBS was injected 
directly into the right striatum 10 minutes prior to ICH, at the same 
coordinates where ICH was induced. For experiments where mice 
were post-treated, TGF-β1 or PBS was delivered by intracerebroven-
tricular (i.c.v.) injections 0.5 mm posterior and 0.75 mm lateral to 
bregma (57) 4 hours following ICH surgery.
Behavioral testing. Mice were behaviorally tested for up to 14 days 
after ICH to examine neurological deficits and functional recovery 
after ICH. All behavioral testing was performed by an observer blinded 
to genotype and treatment. Mice performed cylinder test 1, 3, 7, and 14 
days after ICH as previously described (56). Briefly, mice were placed 
in a clear cylinder and allowed to freely rear for 20 rears, and the first 
forelimb placed was recorded. A laterality index was calculated [(right 
– left)/(right + left + both)], in which greater positive numbers indi-
cate a more severe left hemiparesis (58). For the corner turn test, the 
mouse was allowed to proceed into a 30° corner and then freely turn 
either left or right to exit the corner. The choice of direction during 
10 trials was recorded and the percentage of left turns was calculated. 
For beam walking test, mice were placed on a copper pipe suspended 
40 cm above a table top at 1 or 14 days after ICH. Each mouse was 
given 5 trials to cross the beam and the furthest distance was recorded 
(59). Based on our experience in previous experiments, success on the 
test was defined as being able to walk a distance 20 cm or greater. For 
forced run test, mice were placed in an enclosed treadmill 14 days after 
ICH and forced to run at certain speeds (60). The top speed the mouse 
could run was recorded. Mice were tested only once on the beam walk-
ing test and forced run test to avoid learning effects.
Primary microglial cultures. Primary microglial cultures were 
created as previously described (61). Briefly, cortices were dissected 
from P0–P3 male, WT pups. Brains were dissociated using the neural 
dissociation kit with papain (Miltenyi Biotec) and the cell suspension 
was plated in T75 flasks in L929 media. Microglia were grown on an 
astrocyte bed for 2 weeks and then gently shaken off from the astro-
cyte layer. Supernatants containing the microglia were collected and 
spun down. Microglial purity was determined by flow cytometry (Sup-
plemental Figure 7). Cells were counted and plated at 50,000 cells 
per well in DMEM media supplemented with 10% fetal bovine serum, 
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for CD11b (purified and biotinylated forms used; eBioscience, 1:300) 
and pSMAD2 (Millipore, 1:500). Slides were washed twice and then 
stained with secondary antibodies goat anti-rat–Cy3 and goat anti- 
rabbit–DyLight 488 (Life Technologies, 1:500). Nuclei were stained 
with DAPI. Photographs were taken on a Leica DMi8 using the pro-
vided Leica LAS X software. Adjustments we made using the LAS X 
software. Sections were analyzed by an observer blinded to genotype.
Iron staining. DAB-enhanced Perls’ staining was used to detect 
iron accumulation. Briefly, sections from PBS- and TGF-β1–injected 
brain tissue were washed with PBS and incubated in freshly prepared 
Perls’ solution (5% potassium ferrocyanide/10% hydrochloric acid) 
for 30 minutes, followed by 5 PBS washes. After DAB incubation for 
1.5 minutes and hematoxylin counterstaining, iron deposition in the 
perihemorrhagic area was digitized by microscope. Iron-positive 
cells were counted from 4 high-powered fields/mouse by an observer 
blinded to treatment.
Statistics: murine data. Based on means and standard errors of cyl-
inder testing from prior work, an n = 8 is required to achieve 80% pow-
er to detect a 25% difference in laterality between groups at α = 0.05 
(65). Cylinder testing performed at multiple time points was evaluated 
by repeated measures ANOVA. Top running speed was evaluated by 
Wilcoxon rank sum test since the distribution was non-normal. Beam 
walk test was analyzed by χ2 test. Analysis of intracellular staining, 
primary cell culture gene expression, and ELISA were measured by 
ANOVA followed by Tukey’s post hoc test. Cell sorted microglial gene 
expression and percent of pSMAD+CD11b+ cells from IHC images was 
analyzed by Student’s t test.
Patient cohort study. Patients were prospectively enrolled from 
Hartford Hospital (2010 to 2013) and the Hospital of the University of 
Pennsylvania (2008 to 2011). Blood was collected by peripheral veni-
puncture into lithium heparin tubes at 6 ± 6 hours and 72 ± 6 hours 
after ICH symptom onset (or last known well) and centrifuged at 2000 
g for 10 minutes. Plasma was collected and then centrifuged at 15,000 
g to remove residual platelets and the supernatant frozen at –80°C 
until analysis. Clinical data — including age, sex, volume of ICH, pres-
ence of intraventricular hemorrhage, location of ICH, initial Glasgow 
coma scale score, infections, surgical interventions, length of hospi-
talization, and functional outcomes — were prospectively collected. 
Functional outcomes were quantified using the modified Rankin scale 
score determined by a trained member of the Stroke teams at each 
hospital during a clinic visit or structured telephone interview. Control 
patients were identified from the Hartford Hospital outpatient car-
diology clinic and from inpatients admitted to the Hartford Hospital 
stroke service with negative brain MRI scans (stroke mimics).
Statistics analysis: human data. Variables were tested for normality 
and reported as mean ± SD (if normal), median [interquartile range] 
(if skewed), or number (%). TGF-β1 levels were non-normally distrib-
uted. Patients were dichotomized by whether there was an increase or 
decrease in TGF-β1 levels between the two time points a priori based 
on the results of the murine studies. Univariate analyses were con-
ducted to detect differences in clinical variables between the groups 
by Student’s t test, Fisher’s exact test, or Mann-Whitney U test, as 
appropriate. A multivariable model was created to determine the inde-
pendent association of TGF-β1 response with functional disability at 
90 days by ordered logistical regression while adjusting for the ICH 
score. The proportional odds assumption was checked and upheld. All 
statistical analyses were performed using Stata v11.
circle were labeled on the plot, and each sample was plotted and color 
coded. Heatmaps were created using MATLAB and GENE-E, a matrix 
visualization software available through the Broad Institute (http://
www.broadinstitute.org). Enrichment analysis was performed using 
the Cytoscape (v3.3.0) plugin GeneMania (v3.4.0). Genes appearing in 
the lower-left quadrant of our PCA were used for GeneMANIA anal-
ysis with the following network interactions: coexpression, pathway, 
physical interaction, and shared protein domains. GO biological pro-
cess–based weighting was used.
Intracellular staining for cytokine phosphorylation status by flow 
cytometry. To measure pSMAD2/3, primary microglia were stimulated 
with 10 U/ml thrombin with and without 10 ng TGF-β1 for 20 minutes 
prior to fixation with 4% paraformaldehyde. Cells were permeabilized 
with ice-cold methanol for a minimum of 20 minutes on ice. Cells 
were then stained for CD45 (30-F11, eBioscience), CD11b (M1/70, 
Tonbo Biosciences), and pSMAD2/3 (O72-670, BD Biosciences). To 
measure pSTAT6 in perihematomal regions, mice were sacrificed 
at 7 days and samples were prepared as described above. Cells were 
stained for CD45 (30-F11, eBioscience), CD11b (M1/70, Tonbo Bio-
sciences), CD3e (500A2, BD Biosciences), Ly6C (HK1.4, eBioscienc-
es), and pSTAT6 (J71-773.58.11, BD Biosciences). For measuring TNF 
production, primary microglia were treated for 8 hours as described 
above with the presence of Brefeldin A for 5 hours. Cells were washed 
from Accutase with PBS and then stained with antibodies to cell sur-
face markers CD45 (30-F11, eBioscience) and CD11b (M1/70, Tonbo 
Biosciences) for 20 minutes at room temperature. Cells were fixed (BD 
CytoFix/CytoPerm) for 20 minutes at 4°C prior to being permeabilized 
and stained with antibodies to intracellular TNF (MP6-XT22, BioLeg-
end) for 30 minutes at 4°C. Cells were run on a BD LSRFortessa.
ELISA and multiplex. Perihematomal brains were harvested from 
naive mice and mice 1, 3, 7, 10, and 14 days after ICH and hemisphere 
were separated. Hemispheres were homogenized using 1mm glass 
beads in RIPA buffer (Cell Signaling Technology) containing phospha-
tase and protease inhibitors (Roche) in a bead beater. Samples were 
spun at 8,000 relative centrifugal force (rcf) for 30 seconds to remove 
bubbles, sonicated, and spun at 14,000 rcf for 15 minutes. BCA assay 
was performed to quantify total amount of protein in each hemisphere. 
Eighty micrograms of brain tissue was plated per well. For ELISA on 
cell supernatants, supernatants were harvested from cells stimulated 
for 24 hours. Ten microliters of supernatants were loaded per well for 
TNF and IL-6, and 50 μl cell supernatants were loaded per well for 
BDNF ELISAs. IL-6, CCL2, IL-10, IL-13, IL-17, and IL-4 concentrations 
were measured by multiplex ELISA (Millipore). TGF-β1 (eBioscience) 
and BDNF (Promega) concentrations were measured using commer-
cially available kits. For mouse serum TGF-β1 levels, 100 μl blood was 
collected by cardiac puncture at sacrifice and allowed to clot on ice for 
20 minutes then spun at 2000 g for 10 minutes. Supernatants were 
collected and frozen at –80°C until analysis. Samples for TGF-β1 and 
BDNF ELISAs were acidified with 1N HCl for 10 minutes, then neu-
tralized with 1N NaOH prior to performing the ELISAs.
Immunofluorescence. Mice were sacrificed at 7 and 14 days after 
ICH and transcardially perfused with 20 ml PBS followed by 20 ml 4% 
paraformaldehyde. Brains were then harvested and post-fixed in 4% 
paraformaldehyde overnight at 4°C. Brains were then submerged in 
30% sucrose for 48 hours and embedded in OCT. Seven-micrometer 
sections were cut and blocked with 2% normal goat serum for 1 hour 
at room temperature. Samples were stained with primary antibodies 
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